ERBB2 and breast cancer: BCSCs are reported as being implicated in the chemoresistance to drug classes such as anthracyclines, aromatase inhibitors, estrogen receptor antagonists, recombinant monoclonal anti-HER2 antibodies, and paclitaxel—all utilized in the treatment of BC [39,77].